Victoria L.  Brown net worth and biography

Victoria Brown Biography and Net Worth

As the Rare Disease Program Executive, Vicky oversees the late stage development and commercialization of rare disease assets in Hematology, Nephrology and Neurology. Prior to joining Apellis, Vicky worked at Biogen in Cambridge, MA from 2009 to February 2019 with progressive leadership roles in US and Global functions. Vicky served as Senior Director US Marketing for Biogen’s flagship brands and MS pipeline. Prior to this, Vicky was a Global Commercial Lead with responsibility for the global strategy and commercialization of a franchise of pre-launch and inline products. Whilst at Biogen, Vicky also led the Marketing Excellence Function contributing to multiple successful product launches in the Neurology and Hematology space. Prior to Biogen, Vicky held numerous commercial leadership positions with increasing levels of scope and responsibility in the UK. While at Jansen, she served as the Marketing lead for the Infectious Diseases Business Unit for the UK and Ireland with responsibility for numerous product launches in the infectious diseases space. Vicky began her career in Sales with Janssen UK. Vicky received a B.Sc. (Hons) in Health Sciences from the University of Aberdeen, UK.

What is Victoria L. Brown's net worth?

The estimated net worth of Victoria L. Brown is at least $1.00 million as of June 17th, 2022. Ms. Brown owns 24,974 shares of Apellis Pharmaceuticals stock worth more than $1,000,708 as of June 19th. This net worth approximation does not reflect any other assets that Ms. Brown may own. Learn More about Victoria L. Brown's net worth.

How do I contact Victoria L. Brown?

The corporate mailing address for Ms. Brown and other Apellis Pharmaceuticals executives is 100 FIFTH AVENUE, WALTHAM MA, 02451. Apellis Pharmaceuticals can also be reached via phone at (617) 977-5700 and via email at [email protected]. Learn More on Victoria L. Brown's contact information.

Has Victoria L. Brown been buying or selling shares of Apellis Pharmaceuticals?

Victoria L. Brown has not been actively trading shares of Apellis Pharmaceuticals over the course of the past ninety days. Learn More on Victoria L. Brown's trading history.

Who are Apellis Pharmaceuticals' active insiders?

Apellis Pharmaceuticals' insider roster includes Caroline Baumal (Insider), Victoria Brown (Insider), James Chopas (CAO), Mark DeLong (SVP), Pascal Deschatelets (Insider), A. Dunlop (Director), Jeffrey Eisele (Insider), Cedric Francois (CEO), Federico Grossi (Insider), Karen Lewis (Insider), Alec Machiels (Director), Nur Nicholson (Insider), Nicole Perry (VP), Lukas Scheibler (Insider), Timothy Sullivan (CFO), Adam Townsend (Insider), and David Watson (General Counsel). Learn More on Apellis Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Apellis Pharmaceuticals?

During the last twelve months, insiders at the sold shares 49 times. They sold a total of 776,863 shares worth more than $42,616,032.50. The most recent insider tranaction occured on May, 8th when insider Pascal Deschatelets sold 78,907 shares worth more than $3,341,711.45. Insiders at Apellis Pharmaceuticals own 6.8% of the company. Learn More about insider trades at Apellis Pharmaceuticals.

Information on this page was last updated on 5/8/2024.

Victoria L. Brown Insider Trading History at Apellis Pharmaceuticals

See Full Table

Victoria L. Brown Buying and Selling Activity at Apellis Pharmaceuticals

This chart shows Victoria L. Brown's buying and selling at Apellis Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Apellis Pharmaceuticals Company Overview

Apellis Pharmaceuticals logo
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $40.07
Low: $39.53
High: $41.19

50 Day Range

MA: $44.14
Low: $39.25
High: $55.73

2 Week Range

Now: $40.07
Low: $19.83
High: $92.61


802,046 shs

Average Volume

1,032,409 shs

Market Capitalization

$4.86 billion

P/E Ratio


Dividend Yield